These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

651 related articles for article (PubMed ID: 28240184)

  • 21. Where Do Recent Small Molecule Clinical Development Candidates Come From?
    Brown DG; Boström J
    J Med Chem; 2018 Nov; 61(21):9442-9468. PubMed ID: 29920198
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practices in Molecular Docking and Structure-Based Virtual Screening.
    Dos Santos RN; Ferreira LG; Andricopulo AD
    Methods Mol Biol; 2018; 1762():31-50. PubMed ID: 29594766
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding thermodynamics discriminates fragments from druglike compounds: a thermodynamic description of fragment-based drug discovery.
    Williams G; Ferenczy GG; Ulander J; Keserű GM
    Drug Discov Today; 2017 Apr; 22(4):681-689. PubMed ID: 27916639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrating virtual screening and combinatorial chemistry for accelerated drug discovery.
    López-Vallejo F; Caulfield T; Martínez-Mayorga K; Giulianotti MA; Nefzi A; Houghten RA; Medina-Franco JL
    Comb Chem High Throughput Screen; 2011 Jul; 14(6):475-87. PubMed ID: 21521151
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methods for docking small molecules to macromolecules: a user's perspective. 2. Applications.
    Campagna-Slater V; Therrien E; Weill N; Moitessier N
    Curr Pharm Des; 2014; 20(20):3360-72. PubMed ID: 23947644
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists.
    Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M
    Curr Top Med Chem; 2015; 15(20):2032-42. PubMed ID: 25986689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fragment-Based Drug Discovery for RNA Targets.
    Lundquist KP; Panchal V; Gotfredsen CH; Brenk R; Clausen MH
    ChemMedChem; 2021 Sep; 16(17):2588-2603. PubMed ID: 34101375
    [TBL] [Abstract][Full Text] [Related]  

  • 28. From fragment screening to potent binders: strategies for fragment-to-lead evolution.
    Eitner K; Koch U
    Mini Rev Med Chem; 2009 Jul; 9(8):956-61. PubMed ID: 19601891
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fragment based drug design: from experimental to computational approaches.
    Kumar A; Voet A; Zhang KY
    Curr Med Chem; 2012; 19(30):5128-47. PubMed ID: 22934764
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fragment-to-Lead Medicinal Chemistry Publications in 2019.
    Jahnke W; Erlanson DA; de Esch IJP; Johnson CN; Mortenson PN; Ochi Y; Urushima T
    J Med Chem; 2020 Dec; 63(24):15494-15507. PubMed ID: 33226222
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    de Souza Neto LR; Moreira-Filho JT; Neves BJ; Maidana RLBR; Guimarães ACR; Furnham N; Andrade CH; Silva FP
    Front Chem; 2020; 8():93. PubMed ID: 32133344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Introduction to fragment-based drug discovery.
    Erlanson DA
    Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives on Fragment-based Drug Discovery: A Strategy Applicable to Diverse Targets.
    Li Q; Kang C
    Curr Top Med Chem; 2021; 21(13):1099-1112. PubMed ID: 34348623
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fragment-based screening with natural products for novel anti-parasitic disease drug discovery.
    Liu M; Quinn RJ
    Expert Opin Drug Discov; 2019 Dec; 14(12):1283-1295. PubMed ID: 31512943
    [No Abstract]   [Full Text] [Related]  

  • 35. Virtual fragment preparation for computational fragment-based drug design.
    Ludington JL
    Methods Mol Biol; 2015; 1289():31-41. PubMed ID: 25709031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Using DNA-encoded libraries of fragments for hit discovery of challenging therapeutic targets.
    Zhao G; Zhu M; Li Y; Zhang G; Li Y
    Expert Opin Drug Discov; 2024 Jun; 19(6):725-740. PubMed ID: 38753553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Using fragment-based technologies to target protein-protein interactions.
    Bower JF; Pannifer A
    Curr Pharm Des; 2012; 18(30):4685-96. PubMed ID: 22650253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational Screening and Design for Compounds that Disrupt Protein-protein Interactions.
    Johnson DK; Karanicolas J
    Curr Top Med Chem; 2017; 17(23):2703-2714. PubMed ID: 28482793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Practical Perspective on the Roles of Solution NMR Spectroscopy in Drug Discovery.
    Li Q; Kang C
    Molecules; 2020 Jun; 25(13):. PubMed ID: 32605297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effective progression of nuclear magnetic resonance-detected fragment hits.
    Eaton HL; Wyss DF
    Methods Enzymol; 2011; 493():447-68. PubMed ID: 21371601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.